新疆汉族鼻咽癌患者HLA-A*02基因表达及多态性分析
网络出版日期: 2015-01-29
基金资助
国家自然科学基金(81160327);新疆维吾尔自治区国际合作基金(20126024;201141138)
Analysis of gene expression and polymorphism of allele HLA-A*02 of Han patients with nasopharyngeal carcinoma in Xinjiang
Online published: 2015-01-29
Supported by
National Natural Science Foundation of China, 81160327; The Xinjiang International Collaboration Foundation of China, 20126024, 201141138
目的 探讨新疆汉族鼻咽癌患者HLA-A*02等位基因及其亚型的表达与鼻咽癌发病的关系。方法 采用聚合酶链反应/序列特异性引物(PCR-SSP)的方法对63例新疆汉族鼻咽癌患者和51名汉族健康志愿者HLA-A等位基因进行分析,比较2组HLA-A*02等位基因及其亚型的差异。结果 鼻咽癌患者共检出HLA-A*02等位基因51个(频率39.7%),健康人群检出HLA-A*02等位基因17个(频率16.7%),2组比较差异有统计学意义(P=0.002);鼻咽癌患者共检出7个HLA-A*02等位基因亚型,健康人群检出4个等位基因亚型,2组比较差异无统计学意义(P>0.05),各亚型构成比比较差异无统计学意义(P>0.05)。结论 HLA-A*02等位基因与新疆汉族鼻咽癌患者的发病有关,新疆鼻咽癌患者HLA-A*02等位基因亚型分布存在自身特点。
刘 凯 , 谭 遥 , 李亚伟 , 等 . 新疆汉族鼻咽癌患者HLA-A*02基因表达及多态性分析[J]. 上海交通大学学报(医学版), 2015 , 35(1) : 59 . DOI: 11.3969/j.issn.1674-8115.2015.01.011
Objective To explore the relationship between the polymorphism of allele HLA-A*02 and the incidence of nasopharyngeal carcinoma (NPC) of Han patients in Xinjiang. Methods Polymerase chain reaction/sequence-specific primers (PCR-SSP) method was adopted to analyze HLA-A alleles of 63 Han patients with NPC in Xinjiang and 51 health Han volunteers. The differences of allele HLA-A*02 and its subtypes of two groups were compared. Results The frequency of allele HLAA*02 in NPC patients was 39.7% (51/126) and the frequency of allele HLA-A*02 in healthy people was 16.7% (17/102). The difference was statistically significant (P=0.002). Seven subtypes of allele HLA-A*02 were detected in NPC patients and 4 subtypes of allele HLA-A*02 were detected in healthy people. The difference was not statistically significant (P>0.05). The differences of constituent ratios of subtypes were not statistically significant (P>0.05). Conclusion The allele HLA-A*02 is relevant to the incidence of NPC of Han patients in Xinjiang. The distribution of subtypes of allele HLA-A*02 of NPC patients in Xinjiang have their own features.
Key words: head and neck cancer; nasopharyngeal carcinoma; HLA; polymorphism; T cell immunity
/
〈 |
|
〉 |